Proteomics in hematologic malignancies

Expert Review of Proteomics

Volumn 2, Issue 4, 2005, Pages 567-576

  Caron, Michel ^a   Joubert Caron, Raymonde ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Apoptosis; Azacytidine; Burkirt lymphoma; Databases; Diagnostic; Hematology; Leukemia; Lymphoblast

Indexed keywords

ALPHA ACTININ; AMPHOTERICIN B; AZACITIDINE; CD45 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GALACTOKINASE; GALECTIN 1; GENE PRODUCT; PYRUVATE KINASE; TROPOMYOSIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BURKITT LYMPHOMA; CANCER CELL; CANCER THERAPY; DIFFERENTIAL DISPLAY; DRUG IDENTIFICATION; ELECTROPHORESIS; FUNCTIONAL PROTEOMICS; GENE FUNCTION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 23744513387     PISSN: 14789450     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789450.2.4.567     Document Type: Review

References (60)

1. Blackstock WP, Weir MP. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 17(3), 121-127 (1999).
2. Lutomski D, Caron M, Cornillot JD et al. Identification of different galectins by immunoblotting after two-dimensional polyacrylamide gel electrophoresis with immobilized pH gradients. Electrophoresis 17(3), 600-606 (1996).
3. Lutomski D, Fouillit M, Bourin P et al. Externalization and binding of galectin-1 on cell surface of K562 cells upon erythroid differentiation. Glycobiology 7(8), 1193-1199 (1997).
4. Joubert-Caron R, Feuillard J, Kohanna S et al. A computer-assisted two-dimensional gel electrophoresis approach for studying the variations in protein expression related to an induced functional repression of NFκB in lymphoblastoid cell lines. Electrophoresis 20(4-5), 1017-1026 (1999).
5. Fouillit M, Poirier F, Monostori E et al. Analysis of galectin 1-mediated cell signaling by combined precipitation and electrophoresis techniques. Electrophoresis 21(2), 275-280 (2000).
6. Joubert-Caron R, Le Caer JP, Montandon F et al. Protein analysis by mass spectrometry and sequence database searching: a proteomic approach to identify human lymphoblastoid cell line proteins. Electrophoresis 21(12), 2566-2575 (2000).
7. Poirier F, Imam N, Pontet M, Joubert-Caron R, Caron M. The BPP (protein biochemistry and proteomics) two-dimensional electrophoresis database. J. Chromatogr. B Biomed. Sci. Appl. 753(1), 23-28 (2001).
8. Poirier F, Pontet M, Labas V et al. Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: protein pattern changes following treatment with 5′ - azycytidine. Electrophoresis 22(9), 1867-1877 (2001).
9. Poirier F, Joubert-Caron R, Labas V, Caron M. Proteomic analysis of a lymphoma-derived cell line (DG75) following treatment with a demethylating drug: modification of membrane-associated proteins. Proteomics 3(6), 1028-1036 (2003).
10. Imam-Sghiouar N, Joubert-Caron R, Caron M. Application of metal-chelate affinity chromatography to the study of the phosphoproteome. Amino Acids 28(1), 105-109 (2005).
11. Brockstedt E, Rickers A, Kostka S et al. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J. Biol. Chem. 273(43), 28057-28064 (1998). Describes the use of proteomics to study apoptosis in hematologic cells.
12. Gerner C, Frohwein U, Gotzmann J et al. The Fas-induced apoptosis analyzed by high-throughput proteome analysis. J. Biol. Chem. 275(50), 39018-39026 (2000).
13. Thiede B, Siejak F, Dimmler C, Jungblut PR, Rudel T. A two dimensional electrophoresis database of a human Jurkat T-cell line. Electrophoresis 21(13), 2713-2720 (2000). Describes a standard database of marker proteins.
14. Toda T, Sugimoto M. Proteome analysis of Epstein-Barr virus-transformed B-lymphoblasts and the proteome database. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 787(1), 197-206 (2003).
15. Hanash SM, Madoz-Gurpide J, Misek DE. Identification of novel targets for cancer therapy using expression proteomics. Leukemia 16(4), 478-485 (2002). Survey of a research of several years for proteomic profiling and research of markers applied to hematologic malignancies.
16. Cristea IM, Gaskell SJ, Whetton AD. Proteomics techniques and their application to hematology. Blood 103(10), 3624-3634 (2004).
17. Wennborg A, Classon M, Klein G, von Gabain A. Downregulation of c-myc expression after heat shock in human B-cell lines is independent of 5′ mRNA sequences. Biol. Chem. Hoppe Seyler 376(11), 671-680 (1995).
18. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 101(4), 1220-1235 (2003).
19. Marano N, Holowka D, Baird B. Bivalent binding of an antiCD3 antibody to Jurkat cells induces association of the T-cell receptor complex with the cytoskeleton. J. Immunol. 143(3), 931-938 (1989).
20. Weis M, Schlegel J, Kass GE et al. Cellular events in Fas/APO-1-mediated apoptosis in JURKAT T-lymphocytes. Exp. Cell Res. 219(2), 699-708 (1995).
21. Schraven B, Peter ME. APO-1(CD95)-mediated apoptosis in Jurkat cells does not involve src kinases or CD45. FEBS Lett. 368(3), 491-494 (1995).
22. Joubert-Caron R, Caron M. Proteome analysis in the study of lymphoma cells. Mass Spectrom. Rev. 24(4), 455-468 (2005). Describes several approaches to study the proteome of lymphoma cells.
23. Smith DL, Evans CA, Pierce A, Gaskell SJ, Whetton AD. Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation. Mol. Cell. Proteomics 1(11), 876-884 (2002). Elegant work showing the different information obtained by transcriptomics and proteomics.
24. Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278(46), 45082-45093 (2003). Describes an approach using proteomics to study drug response.
25. Verrills NM, Kavallaris M. Drug resistance mechanisms in cancer cells: a proteomics perspective. Curr. Opin. Mol. Ther. 5(3), 258-265 (2003).
26. Turtinen LW, Prall DN, Bremer LA, Nauss RE, Hartsel SC. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob. Agents Chemother. 48(2), 396-403 (2004).
27. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 249, 135-164 (2000).
28. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br. J. Cancer 64(1), 144-148 (1991).
29. Silverman LR, Holland JF, Weinberg RS et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl. 1), 21-29 (1993).
30. Ben-Bassat H, Goldblum N, Mitrani S et al. Establishment in continuous culture of a new type of lymphocyte from a 'Burkitt like' malignant lymphoma (line D.G.-75). Int. J. Cancer 19(1), 27-33 (1977).
31. Poirier F, Bourin P, Bladier D, Joubert-Caron R, Caron M. Effect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36. Cancer Cell Int. 1(1), 2 (2001).
32. Chatterjee S, Bhattacharya S. Detoxication of industrial pollutants by the glutathione glutathione-S-transferase system in the liver of Anabas testudineus (Bloch). Toxicol. Lett. 22(2), 187-198 (1984).
33. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17(25), 3247-3259 (1998).
34. Rickers A, Brockstedt E, Mapara MY et al. Inhibition of CPP32 blocks surface IgM-mediated apoptosis and D4-GDI cleavage in human BL60 Burkitt lymphoma cells. Eur. J. Immunol. 28(1), 296-304 (1998).
35. Rabinovich GA, Riera CM, Sotomayor CE. Galectin-1, an alternative signal for T-cell death, is increased in activated macrophages. Braz. J. Med. Biol. Res. 32(5), 557-567 (1999).
36. Cosma A. Affinity biotinylation: nonradioactive method for specific selection and labeling of cellular proteins. Anal. Biochem. 252(1), 10-14 (1997).
37. Cornillot JD, Pontet M, Dupuy C et al. Production and characterization of a monoclonal antibody able to discriminate galectin-1 from galectin-2 and galectin-3. Glycobiology 8(5), 425-432 (1998).
38. Fouillit M, Joubert-Caron R, Poirier F et al. Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B-cells. Glycobiology 10(4), 413-419 (2000).
39. Faris M, Kokot N, Latinis K et al. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by upregulating Fas ligand expression. J. Immunol. 160(1), 134-144 (1998).
40. Thiede B, Dimmler C, Siejak F, Rudel T. Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. J. Biol. Chem. 276(28), 26044-26050 (2001).
41. Imam-Sghiouar N, Laude-Lemaire I, Labas V et al. Subproteomics analysis of phosphorylated proteins: application to the study of B-lymphoblasts from a patient with Scott syndrome. Proteomics 2(7), 828-838 (2002). Approach that can be used to study the phosphoproteome in different models.
42. Maguire PB, Wynne KJ, Harney DF et al. Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics 2(6), 642-648 (2002).
43. Salomon AR, Ficarro SB, Brill LM et al. Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc. Natl Acad. Sci. USA 100(2), 443-448 (2003).
44. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 294(5), 1351-1362 (1999).
45. Wan J, Wang J, Cheng H et al. Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells. Electrophoresis 22(14), 3026-3037 (2001).
46. Braziel RM, Shipp MA, Feldman AL et al. Molecular diagnostics. Hematology (Am. Soc. Hematol. Educ. Program) 279-293 (2003).
47. Hanash SM, Strahler JR, Chan Y et al. Database analysis of protein expression patterns during T-cell ontogeny and activation. Proc. Natl Acad. Sci. USA 90(8), 3314-3318 (1993).
48. Strahler JR, Zhu XX, Hora N et al. Maturation stage and proliferation-dependent expression of dUTPase in human T-cells. Proc. Natl Acad. Sci. USA 90(11), 4991-4995 (1993).
49. Caron M, Imam-Sghiouar N, Poirier F et al. Proteomic map and database of lymphoblastoid proteins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 771(1-2), 197-209 (2002).
50. Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev. Proteomics 1(1), 49-55 (2004).
51. Lin Z, Jenson SD, Lim MS, Elenitoba-Johnson KS. Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod. Pathol. 17(6), 670-678 (2004).
52. Schasfoort RBM. Proteomics-on-a-chip: the challenge to couple lab-on-a-chip unit operations. Expert Rev. Proteomics 1(1), 123-132 (2004). Overview of protein chip-based proteomic technologies, achievements and challenges.
53. Ghobrial IM, McCormick DJ, Kaufmann SH et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 105(9), 3722-3730 (2005).
54. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
55. Ardekani AM, Liotta LA, Petricoin EF III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev. Mol. Diagn. 2(4), 312-320 (2002).
56. Antonucci F, Chilosi M, Santacatterina M, Herbert B, Righetti PG. Proteomics and immunomapping of reactive lymph-node and lymphoma. Electrophoresis 23(2), 356-362 (2002).
57. Antonucci F, Chilosi M, Parolini C et al. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 24(14), 2376-2385 (2003).
58. Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KS. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol. Cell. Proteomics 3(8), 820-833 (2004).
59. Harry JL, Wilkins MR, Herbert BR et al. Proteomics: capacity versus utility. Electrophoresis 21(6), 1071-1081 (2000). Survey of some major problems at different stages of proteomics experiments.
60. Bodovitz S, Joos T. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets. Trends Biotechnol. 22(1), 4-7 (2004).